MDNA:CC News and Press, Medicenna Therapeutics Corp.

Increased cash balance to $37 million following a $20 million investment by RA Capital extending runway into mid-2026 MDNA11 continues to exhibit compelling deep and durable single agent activity and best-in-class potential relative to other IL-2 therapies in clinical development ...

- ABILITY-1 study is currently enrolling patients for the treatment of advanced solid tumors with MDNA11, a novel long-acting IL-2 super-agonist, as a monotherapy or in combination with KEYTRUDA ® , at clinical trial sites in U.S.A., Canada, Australia, and Korea - Monot...

Lomiko Metals Inc. (LMR:CA) is expected to report for Q3 2024 Organto Foods Inc. (OGO:CA) is expected to report for Q1 2024 PreveCeutical Medical Inc. (PREV:CNX) is expected to report for Q1 2024 Blue Horizon Global Capital Corp Com (BHCC:CNX) is expected to report for Q1 2024 Per...

Single treatment with bizaxofusp achieved significant survival benefit (mOS of 13.5 vs. 7.2 months, p=0.009) and reduced risk of death by almost half ( hazard ratio: 0.54, 95% confidence interval: 0.34-0.83) versus a propensity balanced external control (EC) arm irrespective of IL...

MDNA11 demonstrates durable response in pancreatic cancer patient with 100% regression of target and non-target lesions for over 104 weeks and continues to show remission 4 months after stopping treatment Melanoma patient continues to show sustained 100% regression of target lesions ...

TORONTO and HOUSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the development of Superkines, announced today that it will present ...

ASCO has informed the Company that the previously accepted MDNA11 oral abstract has been withdrawn due to alleged violation of their prior publication policy based solely on their review of the abstract presented at AACR 2024. Medicenna disagrees with ASCO’s decision as the AACR ...

Not for distribution to United States news wire services or for dissemination in the United States TORONTO and HOUSTON, April 30, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA) (MDNAF: OTCQB), a cli...

A look at the top 10 most actives in Canada Adventus Mining Corporation (ADZN) rose 7.1% to $0.45 on volume of 4,771,403 shares Guanajuato Silver Company Ltd. (GSVR) fell 15.1% to $0.1825 on volume of 3,755,313 shares BetaPro Natural Gas Leveraged Daily Bull ETF (HNU) fell 2.2% to $3.315 ...

Canadian Investment Regulatory Organization Trade Resumption - MDNA Canada NewsWire TORONTO , April 26, 2024 /CNW/ - Trading resumes in: Company: Medicenna Therapeutics Corp. TSX Symbol: MDNA All Issues: Yes Resumption (ET): 8:30 AM CIRO can m...